Laguna Biotherapeutics

Laguna Biotherapeutics is pioneering a novel class of in vivo immunotherapies using its proprietary QUAIL Platform, which consists of engineered, highly attenuated microbes. These therapies are designed to activate and expand innate T cells to target difficult-to-treat cancers, including high-risk leukemias and solid tumors, potentially offering a safer and more scalable alternative to complex ex vivo cell therapies. The company is advancing a pipeline of programs for hematologic and solid tumors, positioning itself at the intersection of the microbiome and immuno-oncology fields. As a private, preclinical-stage biotech, Laguna seeks to reimagine cancer treatment by harnessing the evolutionary interplay between microbes and the immune system.

The QUAIL Platform: an engineered microbial platform using highly attenuated microbes that cannot grow except within specific immune cells. It is designed to activate powerful innate immune responses in vivo, specifically targeting and expanding innate T cells like γδ T cells and MAIT cells to attack tumors.

Laguna competes in the crowded immuno-oncology space but with a unique microbial approach. It differentiates by targeting innate T cells (γδ T, MAIT) in vivo, competing against ex vivo cell therapies, checkpoint inhibitors, and other novel modalities for difficult-to-treat cancers.